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Abstract
Background Fluid retention is a common adverse event in
patients who receive endothelin (ET) receptor antagonist
therapy, including the highly selective ETA receptor
antagonist, atrasentan.
Objective We performed longitudinal assessments of tho-
racic bioimpedance in patients with type 2 diabetes mel-
litus and nephropathy to determine whether a decrease in
bioimpedance accurately reflected fluid retention during
treatment with atrasentan.
Study Design We conducted a randomized, double-blind,
placebo-controlled study in 48 patients with type 2 diabetes
mellitus and nephropathy who were receiving stable doses
of renin angiotensin system inhibitors and diuretics.
Methods Patients were randomized 1:1:1 to placebo,
atrasentan 0.5 mg, or atrasentan 1.25 mg once daily for
8 weeks. Thoracic bioimpedance, vital signs, clinical
exams, and serologies were taken at weeks 1, 2, 4, 6, and 8,
with the exception of serum hemoglobin, which was not
taken at week 1, and serum brain natriuretic peptide, which
was only taken at baseline, week 4, and week 8.
Results Alterations in bioimpedance were more often
present in those who received atrasentan than in those who
received placebo, though overall differences were not sta-
tistically significant. Transient declines in thoracic bioim-
pedance during the first 2 weeks of atrasentan exposure
occurred before or during peak increases in body weight
and hemodilution (decreased serum hemoglobin).
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Conclusions We conclude that thoracic bioimpedance did
not reflect changes in weight gain or edema with atrasentan
treatment in this study. However, the sample size was
small, and it may be of interest to explore the use of tho-
racic bioimpedance in a larger population to understand its
potential clinical use in monitoring fluid retention in
patients with chronic kidney disease who receive ET
receptor antagonists.
Key Points
Thoracic bioimpedance did not reflect changes in
weight or the development of edema in patients with
type 2 diabetes mellitus and nephropathy treated
with atrasentan.
Thoracic bioimpedance should be tested in a larger
population to understand its potential clinical use in
assessing fluid retention in patients with chronic
kidney disease who receive endothelin receptor
antagonists.
1 Introduction
Endothelin (ET) receptor antagonists are being used or
investigated in disease states that result from pathological
increases in activity of the ET system [1–5]. Atrasentan is a
potent ETA receptor antagonist [6] that reduces proteinuria
in patients with type 2 diabetes mellitus and nephropathy
[1, 4]. Currently, atrasentan is in late clinical development
as a treatment for diabetic nephropathy [7].
In clinical studies, the most frequent adverse events
associated with ET receptor antagonists are weight gain,
edema, and congestive heart failure (CHF) [8–10]. Identi-
fying the extent of peripheral edema is the most commonly
used method to assess fluid retention, but it poorly quan-
tifies the amount of fluid retained and therefore has low
specificity for predicting CHF. Thoracic bioimpedance is
an approved noninvasive method to quantify fluid accu-
mulation in a wide variety of clinical conditions, including
CHF [11–16]. In settings of early or ongoing CHF, reduced
thoracic bioimpedance is a sensitive indicator of pul-
monary fluid accumulation even before the development of
CHF symptoms [17].
This study evaluated the longitudinal effect of two low
doses of atrasentan on fluid retention as measured by dif-
ferent parameters in patients with type 2 diabetes mellitus
with nephropathy who were receiving maximum tolerated
labeled doses of renin angiotensin system (RAS) inhibitors.
The aims were to assess whether atrasentan increased
thoracic fluid accumulation as measured by bioimpedance
and to determine whether changes in bioimpedance corre-
lated with changes in weight, peripheral edema, or diuretic
usage.
2 Methods
2.1 Study Design
This was a phase IIb, randomized, double-blind, placebo-
controlled, parallel-group, multi-center study to examine
the safety of two doses of atrasentan in patients with type 2
diabetes mellitus with nephropathy who were currently
receiving the maximum tolerated labeled daily dose of a
RAS inhibitor.
2.2 Patients
A total of 48 subjects were randomized 1:1:1 to placebo,
atrasentan 0.5 mg, or atrasentan 1.25 mg once daily for
8 weeks. This study included doses of atrasentan within a
previously defined range of doses that established the proof
of concept for the ability of atrasentan to reduce urine
albumin excretion [4]. A sample size of 48 was determined
to have about 85% power to detect the overall treatment
group differences in urine albumin excretion after 8 weeks
of treatment with a one-sided significance level of
a = 0.050. Inclusion criteria included the presence of type
2 diabetes mellitus, a urinary albumin:creatinine ratio
(UACR) C300 and B3500 mg/g determined from the
geometric mean of two first morning void urine specimens,
and current treatment with a RAS inhibitor. The main
exclusion factors were a history of moderate or severe
peripheral edema, facial edema, pulmonary edema, pul-
monary hypertension, or heart failure as defined by the
American College of Cardiology/American Heart Associ-
ation practice guidelines [18]. Subjects with a serum brain
natriuretic peptide (BNP) concentration of C200 pg/ml at
screening were also excluded.
After a screening period of up to 14 days, patients
entered a run-in period of 4 weeks, during which they had
to maintain an estimated glomerular filtration rate (eGFR)
C30 and B75 ml/min/1.73 m2 and systolic blood pressure
(SBP) C110 and B180 mmHg. For those in whom the dose
of RAS inhibitor was not maximal, the run-in period was
extended to 8–12 weeks to allow a stable period of
4 weeks at the maximum tolerated level of RAS inhibition.
For entry into the treatment period, subjects had to receive
an unadjusted dose of RAS inhibitor, UACR had to be
C200 mg/g, and SBP had to be C110 and B180 mmHg.
Diuretics were given unless medically contraindicated.
Placebo or atrasentan treatment was then given for
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8 weeks, after which it was withdrawn, and a follow-up
study visit occurred 30 days later.
Vital signs, clinical exams, thoracic bioimpedance,
serologies, and urine samples (for UACR) were taken at
each study visit (week 1, 2, 4, 6, and 8 after randomization)
with the exception of serum hemoglobin, which was not
taken at week 1, and serum BNP, which was only taken at
baseline, week 4, and week 8. Thoracic bioimpedance
measurements were performed onsite using the ZOE
Fluid Status Monitor (Noninvasive Medical Technologies,
Las Vegas, NV, USA) following supervised training from
the manufacturer using a standardized method for all cen-
ters. The presence of thoracic fluid was estimated by the
inverse relationship between fluid accumulation and
reduced impedance (Ohms). The precision of thoracic
bioimpedance measurements in healthy subjects is ±4%
[17].
2.3 Statistical Methods
All analyses were conducted on the intention-to-treat (ITT)
population, comprising subjects who were randomized and
received at least one dose of study drug; data were analyzed
on the randomly assigned treatment group. Differences
between treatment groups for baseline characteristics and
demographics were tested using one-way analysis of
variance (ANOVA) or Fisher’s exact test. Changes between
baseline and post-baseline visits on continuous measures
were analyzed using a repeated measures analysis model.
The association between a set of subjects’ baseline demo-
graphics and disease characteristics and the incidence of
edema was evaluated using a logistic regression model.
3 Results
Of 199 patients screened, 48 met inclusion criteria and
were randomized (Fig. 1). Each of the three groups con-
tained 16 patients, and 15 (93.8%), 14 (87.5%), and 11
(68.8%) patients completed the study in the placebo,
atrasentan 0.5 mg, and atrasentan 1.25 mg groups,
respectively. The major reason for discontinuing from the
study was adverse events. As shown in Table 1, there was a
statistically significant difference between treatment
groups for age, with a higher mean age in the atrasentan
groups (mean age 69 ± 8 years in the atrasentan 0.5 mg
group and 69 ± 7 in the atrasentan 1.25 mg group) than in
the placebo group (mean age 62 ± 9 years; P = 0.022).
There was also a statistically significant difference between
groups for sex, with more males than females in the pla-
cebo group (87.5%) and the atrasentan 0.5 mg group
(87.5%; P = 0.012).
Fig. 1 Patient disposition
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Other demographics and baseline characteristics were
statistically similar among treatment groups (Table 1).
Therewere no changes inmeanweight in the placebo group
during the treatment period, whereas subjects in the two
atrasentan groups experienced overall significant placebo-ad-
justed weight increases from baseline (Fig. 2a). Repeated
measures analysis revealed placebo-adjusted weight gains of
1.7 and 1.6 kg in the atrasentan 0.5 and 1.25 mg groups,
respectively. Most of the increases in weight occurred by the
second week of treatment (placebo-adjusted weight gains of
1.5 and 2.3 kg in the 0.5- and 1.25-mg groups, respectively, at
week 2;P B 0.005).Weight returned to baseline levels in each
of the atrasentan groups by the 30-day post-treatment visit.
Patients in both atrasentan groups also had significant
declines in serum hemoglobin compared with placebo
(Fig. 2b), with values returning to baseline after drug dis-
continuation. Overall, there was a decrease of 0.47 g/dl in
the 0.5-mg group (P = 0.017) and a decrease of 0.84 g/dl
in the 1.25-mg group (P\ 0.001) after placebo-adjusted
repeated measures analysis. The nadir in hemoglobin
occurred at 4 weeks in the 0.5-mg group (0.69 g/dl
decrease, P\ 0.001 vs. placebo) and at 6 weeks in the
1.25-mg group (0.90 g/dl decrease, P\ 0.001 vs. placebo).
There was an increase in the cumulative incidence of
peripheral edema in all groups, with the 1.25-mg group
showing the largest increase (44%) by week 4 (Fig. 2c).
The majority of cases of peripheral edema were regarded as
mild, and only one patient discontinued the study because
of edema (moderate). The mean duration of edema was
similar in the placebo and 0.5-mg groups (21 and 25 days,
respectively) and was longest in the 1.25-mg group
(37 days). The development of edema was not associated
with sex, age, race, baseline UACR, or chronic kidney
disease (CKD) stage by logistics regression analysis.
Diuretic use [81–97%, P = not significant (NS)] and type
of diuretic (loop, 38–56%; distal, 35–44%) were equally
distributed among the groups, and very few patients had a
change in diuretic dose during the treatment period (one in
placebo, none in the 0.5-mg group, and two in the 1.25-mg
group).
Baseline thoracic bioimpedance measurements did not
differ among the groups (Fig. 2d). Bioimpedance within
the placebo group showed minor fluctuations from baseline
(0.5–1.1 Ohms) throughout the treatment period. In con-
trast, the atrasentan groups showed mean reductions of 1.7
and 2.0 Ohms by week 1 (0.5 mg) and week 2 (1.25 mg),
respectively, amounting to nadir mean declines of 7 and
11% from baseline, respectively. Following these declines,
both atrasentan groups showed increases in bioimpedance
of 16 and 21% at weeks 2 and 4 from their nadir, with
Table 1 Demographics and
baseline characteristics
Variable Placebo (n = 16) Atrasentan
0.5 mg (n = 16) 1.25 mg (n = 16)
Age (years) 62 ± 9 69 ± 8a 69 ± 7a
Male 14 (87.5)b 14 (87.5)b 7 (43.8)
Race
White 11 (68.8) 11 (68.8) 10 (62.5)
Black 4 (25.0) 4 (25.0) 3 (18.8)
Asian 0 0 3 (18.8)
Other 1 (6.3) 1 (6.3) 0
Weight (kg) 99 ± 18 101 ± 17 90 ± 22
SBP (mmHg) 138 ± 15 140 ± 15 141 ± 15
DBP (mmHg) 77 ± 11 73 ± 9 76 ± 9
Serum creatinine (mg/dl) 1.6 ± 0.4 1.7 ± 0.4 1.6 ± 0.4
eGFR (ml/min/1.73 m2) 47 ± 15 45 ± 13 41 ± 8
Hemoglobin (g/dl) 13.5 ± 1.6 13.3 ± 1.7 12.4 ± 1.3
Hematocrit (%) 40.7 ± 4.4 40.2 ± 5.2 37.8 ± 4.0
BNP (pg/ml) 45 ± 40 55 ± 56 56 ± 51
Diuretics 16 (100.0) 13 (81.3) 15 (93.8)
Lipid-lowering drugs 14 (87.5) 14 (87.5) 15 (93.8)
Data are mean ± SD or n (%) unless noted otherwise
BNP brain natriuretic peptide, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate, SBP
systolic blood pressure
a P = 0.022 vs. placebo
b P = 0.012 vs. female
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values returning toward baseline by 6 and 8 weeks,
respectively. Despite these fluctuations within the groups
receiving atrasentan, the overall change in bioimpedance
values was not significantly different from placebo when
analyzed with a repeated measures model.
There were no significant differences in serum crea-
tinine, eGFR, or BNP levels among the three groups during
the treatment period. However, serum BNP levels did show
a 25% increase from baseline at week 4 and a 46% increase
at week 8 (P = 0.06) in the 1.25-mg group (Fig. 3). There
were no differences in mean SBP among the groups,
whereas the mean diastolic blood pressure was significantly
reduced in the 1.25-mg group (-7.1 mmHg; P = 0.004 vs.
placebo). Both doses of atrasentan reduced UACR from
baseline by 28% (0.5 mg) and 35% (1.25 mg) within
2 weeks (P\ 0.05 vs. placebo). These atrasentan-induced
reductions were sustained over the 8 weeks of treatment,
with values returning to baseline after 30 days off study
drug, similar to findings in previous studies [1, 4].
The incidence of AEs was similar across all treatment
groups (Table 2). The most frequently reported AE was
peripheral edema. More patients in the 1.25-mg group
experienced serious AEs, with three patients in this group
discontinuing because of an AE. One patient in the 1.25-
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levels. 1P = 0.06 from change from baseline vs. placebo change from
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mg group also experienced CHF after being hospitalized
for headache. The CHF event occurred concurrently with
pulmonary hypertension and coronary artery stenosis,
7 days after the last dose of atrasentan at treatment week 4
when mild peripheral edema was present. This patient’s
bioimpedance values (Ohms) were as follows: 30.1 (base-
line), 16.3 (week 1), 25.4 (week 2), and 26.2 (week 4).
4 Discussion
To our knowledge, this is the first longitudinal assessment
of thoracic bioimpedance in patients with diabetes and
nephropathy who were receiving an ETA receptor antag-
onist in combination with RAS inhibitors and diuretics.
Overall, there were no significant differences in bioimpe-
dance between the treatment groups and those receiving
placebo, although early decreases in the atrasentan groups
(7–11% decline) by week 2 were observed to coincide with
the initial increases in body weight and declines in serum
hemoglobin. Because these impedance changes were
transient and not associated with pulmonary symptoms of
fluid retention, the clinical relevance of these findings is
unclear. However, recent studies in patients with acute
myocardial infarction showed that a 12% reduction in
thoracic bioimpedance was associated with pulmonary
edema [19], suggesting that the early bioimpedance chan-
ges in our study, if sustained, could have become clinically
apparent.
Because the majority of patients in this study were
receiving diuretics before being randomized, it is possible
they were partially protected against the potential fluid-
retentive effects of atrasentan. Relevant studies in patients
with CHF have demonstrated that furosemide treatment
resulted in an 8% increase in thoracic bioimpedance, which
correlated with increased urinary output (P = 0.004) [20].
It is also possible that endogenous BNP may have had a
diuretic effect in this study. For example, patients receiving
atrasentan 1.25 mg had a 25 and 46% increase in serum
BNP at 4 and 8 weeks post-baseline, respectively, which
may have resulted from an earlier increase in fluid retention
induced by atrasentan. In this hypothetical scenario, the
putative early increase in pulmonary fluid, identified by the
11% decrease in bioimpedance (1.25-mg group), could
have stimulated cardiac production of BNP, which induced
a diuresis that resolved further pulmonary fluid accumu-
lation. The subsequent 21% rise in thoracic bioimpedance
from nadir values would correlate with a decrease in pul-
monary fluid. While the diuretic effect of exogenous BNP
has been described in healthy individuals [21, 22], future
studies are required to more fully assess a potential diuretic
effect of endogenous BNP in response to ET receptor
antagonist therapy in patients with diabetic nephropathy.
These results confirms those from earlier studies show-
ing that atrasentan reduces serum hemoglobin and albu-
minuria while causing weight gain and peripheral edema in
patients with diabetic nephropathy [1, 4]. The atrasentan
doses for this study were chosen to minimize the risk for
edema and, while the group receiving the higher atrasentan
dose in this study had the most patients affected by edema
(50%), a relevant number of patients in the placebo group
(30%) also developed edema by the sixth week of treat-
ment. This calls into question the clinical finding of mild
peripheral edema as it applies to a CKD population. These
results also confirm that most patients who receive
atrasentan do not develop peripheral edema, at least in
short-term treatment protocols. Importantly, the patients in
this and other recent studies with atrasentan have been
Table 2 Treatment-emergent
adverse events
Variable Placebo (n = 16) Atrasentan
0.5 mg (n = 16) 1.25 mg (n = 16)
Any AE 13 (81.3) 13 (81.3) 13 (81.3)
Any serious AE 0 0 6 (37.5)a
Peripheral edema 7 (43.8) 5 (31.3) 8 (50.0)
Generalized edema 0 0 1 (6.3)
Congestive heart failure 0 0 1 (6.3)
Deaths 0 0 0
AE leading to discontinuation 0 0 3 (18.8)
Abdominal discomfort 0 0 1 (6.3)
Fatigue and peripheral edema 0 0 1 (6.3)
Acute kidney injury 0 0 1 (6.3)
Data are n (%)
AE adverse event
a P B 0.05 compared with placebo using Fisher’s exact test
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highly selected for not having a past history of CHF and for
having serum BNP levels \200 pg/ml [1, 4]. Thus, the
potential for atrasentan to cause fluid retention in an un-
selected population of patients with diabetes and
nephropathy remains undefined.
Limitations of this study include the small sample size,
the short duration of treatment, the absence of direct
measures of pulmonary fluid retention, and the limited
range of atrasentan doses tested. In addition, generaliz-
ability to a larger population of patients with diabetes and
CKD is substantially diminished by the high screen fail rate
for entry into the study. Despite these limitations, the fre-
quent longitudinal measurements of thoracic bioimpedance
enabled the detection of hypothetical physiological inter-
actions induced by atrasentan that should be tested in a
larger patient population, particularly with respect to the
effects on patient well-being.
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